tbuckley/cabot-search huggingface dataset:
Obesity is associated with a distinct brain-gut microbiome signature that connects Prevotella and Bacteroides to the brain’s reward center
Authors: Tien S. Dong, Michelle Guan, Emeran A. Mayer, Jean Stains, Cathy Liu, Priten Vora, Jonathan P. Jacobs, Venu Lagishetty, Lin Chang, Robert L. Barry, Arpana Gupta
Journal: Gut Microbes (2022)

The prevalence of obesity has risen to its highest values over the last two decades. While many studies have either shown brain or microbiome connections to obesity, few have attempted to analyze the brain-gut-microbiome relationship in a large cohort adjusting for cofounders. Therefore, we aim to explore the connection of the brain-gut-microbiome axis to obesity controlling for such cofounders as sex, race, and diet. Whole brain resting state functional MRI was acquired, and connectivity and brain network properties were calculated. Fecal samples were obtained from 287 obese and non-obese participants (males n = 99, females n = 198) for 16s rRNA profiling and fecal metabolites, along with a validated dietary questionnaire. Obesity was associated with alterations in the brain's reward network (nucleus accumbens, brainstem). Microbial diversity (p = .03) and composition (p = .03) differed by obesity independent of sex, race, or diet. Obesity was associated with an increase in
PROMINENT A-WAVE DIP IN THE SPECTRAL DOPPLER OF PULMONIC REGURGITATION DESPITE PULMONARY HYPERTENSION: A SIGN OF RIGHT VENTRICULAR DYSFUNCTION
Authors: Lila Kaminsky, Erica Archambeau, Rishi Vohara, Gerard P. Aurigemma, Matthew W. Parker
Journal: Journal of the American College of Cardiology (2022)
Kidney complications of parasitic diseases
Authors: Elizabeth De Francesco Daher, Geraldo Bezerra da Silva Junior, Mayuri Trivedi, Tarek Fayad, Nattachai Srisawat, Sanjeev Nair, Padet Siriyasatien, Marcus Vinícius Guimarães de Lacerda, Maria Alice Sperto Ferreira Baptista, Mahesha Vankalakunti, Vivekanand Jha
Journal: Nature Reviews Nephrology (2022)
A CONTACT-FREE OPTICAL DEVICE FOR THE DETECTION OF INCREASED LUNG FLUID CONTENT
Authors: Ilan Merdler, Aviram Hochstadt, Eihab Ghantous, Lior Lupu, Ariel Borochovich, Yoav Beck, Maxim Shatsky, Ricardo Rubio-Oliver, Sagi Polani, Yaron Arbel
Journal: Journal of the American College of Cardiology (2022)
Anti-cancer activity of sustained release capsaicin formulations
Authors: Justin C. Merritt, Stephen D. Richbart, Emily G. Moles, Ashley J. Cox, Kathleen C. Brown, Sarah L. Miles, Paul T. Finch, Joshua A. Hess, Maria T. Tirona, Monica A. Valentovic, Piyali Dasgupta
Journal: Pharmacology & Therapeutics (2022)
Tom Nolan’s research reviews—17 March 2022
Authors: Tom Nolan
Journal: BMJ (2022)

Radioiodine goes off airRates of death from stage I or II differentiated thyroid cancer are close to zero.An analysis in the Lancet in 2020 estimated over one million thyroid cancer overdiagnoses (over 80% of them in women) between 2008 and 2012 across 26 countries.Even in these low risk cancers, total thyroidectomy with postoperative radioiodine has been the standard treatment.
TRENDS IN CONTRACEPTION USE AMONG WOMEN OF CHILD-BEARING AGE WITH HYPERTENSION IN THE UNITED STATES FROM 2001-2018
Authors: Claire Meyerovitz, Ekaterina Skaritanov, Didem Ayturk, Sharina D. Person, Tara Kumaraswami, Stephen Paul Juraschek, Tiffany A. Moore Simas, Lara Kovell
Journal: Journal of the American College of Cardiology (2022)
MITRAL ANNULAR CALCIFICATION AS A PREDICTOR OF STROKE IN THE MULTI ETHNIC STUDY OF ATHEROSCLEROSIS
Authors: Francesca Calicchio, Afiachukwu Onuegbu, April Kinninger, Rine Nakanishi, John Jeffrey Carr, Khurram Nasir, Rebecca Gottesman, Matthew J. Budoff
Journal: Journal of the American College of Cardiology (2022)
YAP mediates compensatory cardiac hypertrophy through aerobic glycolysis in response to pressure overload
Authors: Toshihide Kashihara, Risa Mukai, Shin-ichi Oka, Peiyong Zhai, Yasuki Nakada, Zhi Yang, Wataru Mizushima, Tsutomu Nakahara, Junco S. Warren, Maha Abdellatif, Junichi Sadoshima
Journal: Journal of Clinical Investigation (2022)

The heart utilizes multiple adaptive mechanisms to maintain pump function. Compensatory cardiac hypertrophy reduces wall stress and oxygen consumption, thereby protecting the heart against acute blood pressure elevation. The nuclear effector of the Hippo pathway, Yes-associated protein 1 (YAP), is activated and mediates compensatory cardiac hypertrophy in response to acute pressure overload (PO). In this study, YAP promoted glycolysis by upregulating glucose transporter 1 (GLUT1), which in turn caused accumulation of intermediates and metabolites of the glycolytic, auxiliary, and anaplerotic pathways during acute PO. Cardiac hypertrophy was inhibited and heart failure was exacerbated in mice with YAP haploinsufficiency in the presence of acute PO. However, normalization of GLUT1 rescued the detrimental phenotype. PO induced the accumulation of glycolytic metabolites, including l-serine, l-aspartate, and malate, in a YAP-dependent manner, thereby promoting cardiac hypertrophy. YAP upregulated the GLUT1 gene through interaction with TEA domain family member 1 (TEAD1) and HIF-1α in cardiomyocytes. Thus, YAP induces compensatory cardiac hypertrophy through activation of the Warburg effect.
PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs
Authors: Eun Hye Kim, Jongwon Lee, Gijung Kwak, Hochung Jang, Hyosuk Kim, Haeun Cho, Yeongji Jang, Jiwoong Choi, Sung-Gil Chi, Kwangmeyung Kim, Ick Chan Kwon, Yoosoo Yang, Sun Hwa Kim
Journal: Journal of Controlled Release (2022)
Destabilizing heterochromatin by APOE mediates senescence
Authors: Hongkai Zhao, Qianzhao Ji, Zeming Wu, Si Wang, Jie Ren, Kaowen Yan, Zehua Wang, Jianli Hu, Qun Chu, Huifang Hu, Yusheng Cai, Qiaoran Wang, Daoyuan Huang, Zhejun Ji, Jingyi Li, Juan Carlos Izpisua Belmonte, Moshi Song, Weiqi Zhang, Jing Qu, Guang-Hui Liu
Journal: Nature Aging (2022)
Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors
Authors: Steven B. Maron, Samuel J. Klempner
Journal: Cancer Discovery (2022)

Summary: Optimizing the utility of tumor mutational burden in solid tumors remains an unmet need and a clinical knowledge gap. Using a centrally determined cutoff of ≥16 mut/Mb, Friedman and colleagues demonstrate an ability to enrich for atezolizumab response in a pretreated pan-cancer multibasket study. See related article by Friedman et al., p. 654 (4).
TNF-α stimulation enhances the neuroprotective effects of gingival MSCs derived exosomes in retinal ischemia-reperfusion injury via the MEG3/miR-21a-5p axis
Authors: Ziyu Yu, Yuwen Wen, Nan Jiang, Zhidong Li, Jieying Guan, Yingying Zhang, Caibing Deng, Ling Zhao, Song Guo Zheng, Yingting Zhu, Wenru Su, Yehong Zhuo
Journal: Biomaterials (2022)

Retinal ischemia-reperfusion injury (IRI) is one of the main pathogenic mechanisms of glaucoma, which are largely unknown, including neuroinflammation and neuronal death in the pathological process. In our previous studies, mesenchymal stem cells (MSCs) have been reported to play anti-inflammatory and neuroprotective roles. Additionally, conditioned culture medium (CM) of MSCs stimulated by TNF-α have achieved better antiallergic effects in an experimental allergic conjunctivitis mouse model. However, there is an urgent need for cell-free therapy approaches, like exosomes, to reduce the side effects of autoimmunity. The present study aimed to elucidate the pathways involving TNF-α-stimulated gingival MSC (GMSC)-exosomes (TG-exos), in modulating inflammatory microglia and alleviating apoptosis. In this study, exosomes from the CM of GMSCs were isolated by ultracentrifugation and were injected into the vitreous of mice. The results showed that intraocular injection of TG-exos into mice with IRI notably reduced inflammation and cell loss than that with G-exos (GMSC-exosomes). Similar results were observed in vitro. Additionally, with the microRNA (miR) arrays, it was found that miR-21-5p acted as a crucial factor in TG-exos for neuroprotection and anti-inflammation. Following target prediction and dual-luciferase assay suggested that miR-21-5p played a role by combining with programmed cell death 4 (PDCD4), which was regulated by the long non-coding RNA (lncRNA) maternally expressed gene 3 (MEG3) as a competing endogenous RNA (ceRNA). This study demonstrates a new therapeutic pathway for neuroprotection against IRI by delivering miR-21-5p-enriched exosomes through MEG3/miR-21-5p/PDCD4 axis and paves the way for the establishment of a cell-free therapeutic approach for glaucoma.
<scp>d</scp>‐Amino Acid‐Based Metabolic Labeling Enables a Fast Antibiotic Susceptibility Test of Both Isolated Bacteria and Bronchoalveolar Lavage Fluid (Adv. Healthcare Mater. 6/2022)
Authors: Juan Gao, Junnan Guo, Jianxiao Chen, Chenling Ding, Jiemin Wang, Qian Huang, Ying Jian, Xianyuan Zhao, Min Li, Yuan Gao, Chaoyong Yang, Wei Wang
Journal: Advanced Healthcare Materials (2022)

Antibiotic Susceptibility Tests After a brief incubation with a fluorescent d-amino acid probe and different doses of antibiotics, the varied labeling intensities of bacterial pathogens, already isolated or still presenting in clinical samples like bronchoalveolar lavage fluid, are analyzed by flow cytometry to reflect their affected metabolic status. The bacterial susceptibilities to the drugs can then be determined accordingly with high accuracies. This work is highlighted in article number 2101736 by Min Li, Yuan Gao, Chaoyong Yang, Wei Wang, and co-workers.
Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity
Authors: Kang Du, Ling Sun, Zichen Luo, Yang Cao, Qiushi Sun, Kangzhen Zhang, Ahmed Faizy, Daniele Piomelli, Xiang Lu, Jinjun Shan, Qin Yang
Journal: Metabolism (2022)
REMOTENESS OF RESIDENCE FROM A SURGICAL PROGRAM BUT NOT SOCIOECONOMIC STATUS IS ASSOCIATED WITH HIGHER IN-HOSPITAL MORTALITY IN INFANTS WITH MAJOR CONGENITAL HEART DISEASE IN A JURISDICTION OF UNIVERSAL HEALTH CARE
Authors: Oluwayomi Olugbuyi, Christopher Smith, Sunjidat Islam, Luke Eckserley, Dover Douglas, Andrew S. Mackie, Padma Kaul, Lisa K. Hornberger
Journal: Journal of the American College of Cardiology (2022)
KRISHNA AKELLA DO
Authors: Sunil Pathak, Robert Burke, Krishna Akella, Andrew Grees, Garry G. Lachhar, Elnaz Mahbub, Veronica Schauer, Rohan Trivedi, Parker Lavigne, Juan Siordia, Daisy Young, Howard Sklarek, Lydia Taranto, Pratik Dalal
Journal: Journal of the American College of Cardiology (2022)
RISK OF PERICARDIAL DISEASE WITH RADIATION THERAPY COMPARED TO RISK OF OTHER ADVERSE CARDIOVASCULAR EVENTS (ACE): DATA FROM THE US FDA ADVERSE EVENT REPORTING SYSTEM (FAERS), A PHARMACOVIGILANCE DATABASE.
Authors: Malak Modi, Sahith Reddy Thotamgari, Akash Pandya, Kalgi A. Modi
Journal: Journal of the American College of Cardiology (2022)
Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function
Authors: Ruihan Tang, Nandini Acharya, Ayshwarya Subramanian, Vinee Purohit, Marcin Tabaka, Yu Hou, Danyang He, Karen O. Dixon, Connor Lambden, Junrong Xia, Orit Rozenblatt-Rosen, Raymond A. Sobel, Chao Wang, Aviv Regev, Ana C. Anderson, Vijay K. Kuchroo
Journal: Science Immunology (2022)

Dendritic cells (DCs) sense environmental cues and adopt either an immune-stimulatory or regulatory phenotype, thereby fine-tuning immune responses. Identifying endogenous regulators that determine DC function can thus inform the development of therapeutic strategies for modulating the immune response in different disease contexts. Tim-3 plays an important role in regulating immune responses by inhibiting the activation status and the T cell priming ability of DC in the setting of cancer. Bat3 is an adaptor protein that binds to the tail of Tim-3; therefore, we studied its role in regulating the functional status of DCs. In murine models of autoimmunity (experimental autoimmune encephalomyelitis) and cancer (MC38-OVA-implanted tumor), lack of Bat3 expression in DCs alters the T cell compartment-it decreases TH1, TH17 and cytotoxic effector cells, increases regulatory T cells, and exhausted CD8+ tumor-infiltrating lymphocytes, resulting in the attenuation of autoimmunity and acceleration of tumor growth. We found that Bat3 expression levels were differentially regulated by activating versus inhibitory stimuli in DCs, indicating a role for Bat3 in the functional calibration of DC phenotypes. Mechanistically, loss of Bat3 in DCs led to hyperactive unfolded protein response and redirected acetyl-coenzyme A to increase cell intrinsic steroidogenesis. The enhanced steroidogenesis in Bat3-deficient DC suppressed T cell response in a paracrine manner. Our findings identified Bat3 as an endogenous regulator of DC function, which has implications for DC-based immunotherapies.
CLINICAL OUTCOMES OF AV NODE ABLATION AND HIS-PURKINJE CONDUCTION SYSTEM PACING VERSUS CONVENTIONAL PACING
Authors: Andrew Mathew, Faiz Ali Subzposh, Wilson Young, Parash Pokharel, Jess William Oren, Randle H. Storm, Angela Naperkowski, Pugazhendhi Vijayaraman
Journal: Journal of the American College of Cardiology (2022)
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Authors: Osama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, Howard Streicher, Emma Hathaway, Rachel Cunningham, Michael Manos, Mariano Severgnini, Scott Rodig, F Stephen Hodi
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. Methods This is a multicenter phase IB dose-escalation study of the combination of ziv-aflibercept (at 2–4 mg/kg) plus pembrolizumab (at 2 mg/kg) administered intravenously every 2 weeks with expansion cohorts in programmed cell death protein 1 (PD-1)/programmed death-ligand 1(PD-L1)-naïve melanoma, renal cell carcinoma (RCC), microsatellite stable colorectal cancer (CRC), and ovarian cancer. The primary objective was to determine maximum tolerated dose (MTD) and recommended dose of the combination. Secondary endpoints included overall response rate (ORR) and overall survival (OS). Exploratory objectives included correlation of clinical efficacy with tumor and peripheral immune population densities. Results Overall, 33 patients were enrolled during dose escalation (n=3) and dose expansion (n=30). No dose-limiting toxicities were reported in the initial dose level. Ziv-aflibercept 4 mg/kg plus pembrolizumab 2 mg/kg every 2 weeks was established as the MTD. Grade ≥3 adverse events occurred in 19/33 patients (58%), the most common being hypertension (36%) and proteinuria (18%). ORR in the dose-expansion cohort was 16.7% (5/30, 90% CI 7% to 32%). Complete responses occurred in melanoma (n=2); partial responses occurred in RCC (n=1), mesothelioma (n=1), and melanoma (n=1). Median OS was as follows: melanoma, not reached (NR); RCC, 15.7 months (90% CI 2.5 to 15.7); CRC, 3.3 months (90% CI 0.6 to 3.4); ovarian, 12.5 months (90% CI 3.8 to 13.6); other solid tumors, NR. Activated tumor-infiltrating CD8 T cells at baseline (CD8+PD1+), high CD40L expression, and increased peripheral memory CD8 T cells correlated with clinical response. Conclusion The combination of ziv-aflibercept and pembrolizumab demonstrated an acceptable safety profile with antitumor activity in solid tumors. The combination is currently being studied in sarcoma and anti-PD-1-resistant melanoma. Trial registration number NCT02298959 .
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression
Authors: Liping Li, Jung-Hyun Kim, Wenyan Lu, Donna M. Williams, Joseph Kim, Leslie Cope, Raajit K. Rampal, Richard P. Koche, Lingling Xian, Li Z. Luo, Marija Vasiljevic, Daniel R. Matson, Zhizhuang Joe Zhao, Ophelia Rogers, Matthew C. Stubbs, Karen Reddy, Antonio-Rodriguez Romero, Bethan Psaila, Jerry L. Spivak, Alison R. Moliterno, Linda M. S. Resar
Journal: Blood (2022)
SNPs, short tandem repeats, and structural variants are responsible for differential gene expression across C57BL/6 and C57BL/10 substrains
Authors: Milad Mortazavi, Yangsu Ren, Shubham Saini, Danny Antaki, Celine L. St. Pierre, April Williams, Abhishek Sohni, Miles F. Wilkinson, Melissa Gymrek, Jonathan Sebat, Abraham A. Palmer
Journal: Cell Genomics (2022)

Mouse substrains are an invaluable model for understanding disease. We compared C57BL/6J, which is the most commonly used inbred mouse strain, with eight C57BL/6 and five C57BL/10 closely related inbred substrains. Whole-genome sequencing and RNA-sequencing analysis yielded 352,631 SNPs, 109,096 indels, 150,344 short tandem repeats (STRs), 3,425 structural variants (SVs), and 2,826 differentially expressed genes (DE genes) among these 14 strains; 312,981 SNPs (89%) distinguished the B6 and B10 lineages. These SNPs were clustered into 28 short segments that are likely due to introgressed haplotypes rather than new mutations. Outside of these introgressed regions, we identified 53 SVs, protein-truncating SNPs, and frameshifting indels that were associated with DE genes. Our results can be used for both forward and reverse genetic approaches and illustrate how introgression and mutational processes give rise to differences among these widely used inbred substrains.
Association of the gut microbiome and metabolome with wheeze frequency in childhood asthma
Authors: Kathleen Lee-Sarwar, Sandra Dedrick, Babak Momeni, Rachel S. Kelly, Robert S. Zeiger, George T. O’Connor, Megan T. Sandel, Leonard B. Bacharier, Avraham Beigelman, Nancy Laranjo, Diane R. Gold, Jessica Lasky-Su, Augusto A. Litonjua, Yang-Yu Liu, Scott T. Weiss
Journal: Journal of Allergy and Clinical Immunology (2022)
RATE OF30-DAY READMISSION &amp; ECONOMIC BURDEN IN PATIENTS WHO UNDERWENT TRANSCATHETER AORTIC VALVE REPLACEMENT WITH CO-EXISTING CHRONIC CONGESTIVE HEART FAILURE
Authors: Michael A. Fatuyi, Leanne Pereira, Awfa Zain Elabidin, Vahid Namdarizandi, Bassman Tappuni, Leonid Khokhlov, Jeremiah Oluwadamisi, Asimul H. Ansari, Najamul Ansari, Kamal Shemisa
Journal: Journal of the American College of Cardiology (2022)
SYSTEMIC PULSE PRESSURE TO CENTRAL VENOUS PRESSURE RATIO IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES IN PATIENTS UNDERGOING AORTIC AND MITRAL VALVULAR SURGERY
Authors: Frances Morales, Kajal Shah, Kenneth C. Bilchick, Olivia Ondigi, Khadijah Breathett, Younghoon Kwon, Nishaki Mehta, David Zhou, Jamey Cutts, David Shisler, Sula Mazimba
Journal: Journal of the American College of Cardiology (2022)
29P LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)
Authors: X. Zheng, Q. Ji, Y. Sun, M. Ge, B. Zhang, Y. Cheng, S. Lei, F. Shi, W. Zhang, M. Gao
Journal: Annals of Oncology (2022)
ASSOCIATION BETWEEN INTRACORONARY IMAGING USE DURING PCI AND SUBSEQUENT CLINICAL OUTCOMES IN A REAL-WORLD U.S. MEDICARE CLAIMS DATABASE
Authors: Brian Bergmark, Eric Alan Osborn, Ziad Ali, Aakriti Gupta, Kranthi K. Kolli, Julie Prillinger, Nick E. West, James Hasegawa, Kevin J. Croce, Eric Alexander Secemsky
Journal: Journal of the American College of Cardiology (2022)
Dynamics of the normal gut microbiota: A longitudinal one-year population study in Sweden
Authors: Lisa M Olsson, Fredrik Boulund, Staffan Nilsson, Muhammad Tanweer Khan, Anders Gummesson, Linn Fagerberg, Lars Engstrand, Rosie Perkins, Mathias Uhlén, Göran Bergström, Valentina Tremaroli, Fredrik Bäckhed
Journal: Cell Host & Microbe (2022)

Temporal dynamics of the gut microbiota potentially limit the identification of microbial features associated with health status. Here, we used whole-genome metagenomic and 16S rRNA gene sequencing to characterize the intra- and inter-individual variations of gut microbiota composition and functional potential of a disease-free Swedish population (n = 75) over one year. We found that 23% of the total compositional variance was explained by intra-individual variation. The degree of intra-individual compositional variability was negatively associated with the abundance of Faecalibacterium prausnitzii (a butyrate producer) and two Bifidobacterium species. By contrast, the abundance of facultative anaerobes and aerotolerant bacteria such as Escherichia coli and Lactobacillus acidophilus varied extensively, independent of compositional stability. The contribution of intra-individual variance to the total variance was greater for functional pathways than for microbial species. Thus, reliable quantification of microbial features requires repeated samples to address the issue of intra-individual variations of the gut microbiota.
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
Authors: João Pedro Ferreira, Javed Butler, Faiez Zannad, Gerasimos Filippatos, Elke Schueler, Dominik Steubl, Cordula Zeller, James L. Januzzi, Stuart Pocock, Milton Packer, Stefan D. Anker
Journal: Journal of the American College of Cardiology (2022)

Mineralocorticoid receptor antagonists (MRAs) may be beneficial in reducing heart failure (HF) hospitalizations in patients with HF with preserved ejection fraction. The effect of sodium-glucose cotransporter 2 inhibitors in patients with HF with preserved ejection fraction according to MRA background therapy has not been reported. The aim of this study was to examine the effect of empagliflozin in MRA users and nonusers in the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) trial. Survival analyses were conducted comparing the effects of empagliflozin vs placebo in MRA users and nonusers at baseline with treatment-by-MRA use interaction terms. A total of 5,988 patients were included, of whom 2,244 (37.5%) were using MRAs at baseline. MRA users had higher event rates than MRA nonusers (placebo group primary outcome 9.4 vs 8.2 events per 100 person-years). The benefit of empagliflozin to reduce the primary outcome was not significantly different between MRA nonusers and MRA users (HR: 0.73 [95% CI: 0.62-0.87] and HR: 0.87 [95% CI: 0.71-1.06]; interaction P = 0.22). The effect of empagliflozin to reduce first and recurrent HF hospitalizations was more pronounced in MRA nonusers than in MRA users (HR: 0.60 [95% CI: 0.47-0.77] and HR: 0.90 [95% CI: 0.68-1.19]; interaction P = 0.038). MRA users experienced almost twice as many hyperkalemia events as MRA nonusers, and empagliflozin reduced the risk for hyperkalemia or initiation of potassium binders regardless of MRA use (MRA nonusers: HR: 0.90 [95% CI: 0.69-1.19]; MRA users: HR: 0.74 [95% CI: 0.56-0.96]; interaction P = 0.29). The benefit of empagliflozin to reduce the primary outcome was not significantly different between MRA nonusers and MRA users. The effect of empagliflozin to reduce first and recurrent HF hospitalizations was more pronounced in MRA nonusers. Empagliflozin reduced hyperkalemia, with no significant treatment-by-MRA subgroup interaction. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPEROR-Preserved]; NCT03057951)
UTILIZATION AND IN-HOSPITAL OUTCOMES OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY VERSUS INTRACARDIAC ECHOCARDIOGRAPHY FOR LEFT ATRIAL APPENDAGE CLOSURE: INSIGHT FROM NATIONWIDE DATABASE
Authors: Mohamed Hamed, Ramez Morcos, Muni Rubens, Anshul Saxena, Emad Samaan, Mohamed Abdelazeem, Omar Hegazy, Beshoy Elkatcha, Daniel Jacobs, Brian Blair, Emir Veledar, Brijeshwar Singh Maini, Houman Khalili
Journal: Journal of the American College of Cardiology (2022)
PROGNOSTIC UTILITY OF REGADENOSON-INDUCED SPLENIC SWITCH-OFF IN RUBIDIUM-82 PET MYOCARDIAL PERFUSION IMAGING
Authors: Jean Michel Saad, Ahmed Ibrahim Ahmed, Yushui Han, Lamees El Nihum, Yajaira Jimenez, Emily Newstrom, Payam Pournazari, Mouaz H. Al-Mallah
Journal: Journal of the American College of Cardiology (2022)